DOCSLIB.ORG

Immediate Anterior Chamber Paracentesis with a 30-Gauge

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Immediate Anterior Chamber Paracentesis with a 30-Gauge perim Ex en l & ta a l ic O p in l h t C h f Journal of Clinical & Experimental a o l m l a o n l r o Kitnarong et al., J Clin Exp Ophthalmol 2017, 8:3 g u y o J Ophthalmology DOI: 10.4172/2155-9570.1000657 ISSN: 2155-9570 Research Article Open Access Immediate Anterior Chamber Paracentesis with a 30-Gauge Needle for Acute Primary Angle Closure Naris Kitnarong1*, Sumalee Boonyaleepun2, Darin Sakiyalak1, Ngamkae Ruangvaravate1 and Ankana Metheetrairut1 1Department of Ophthalmology, Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand 2Department of Ophthalmology, Faculty of Medicine, Sinakarinwirot University, Thailand *Corresponding author: Naris Kitnarong, Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Prannok Road, Bangkoknoi, Bangkok 10700, Thailand, Tel: +662-419-8033; Fax: +662-411-1906; E-mail: [email protected] Received date: October 30, 2016; Accepted date: June 15, 2017; Published date: June 20, 2017 Copyright: ©2017 Kitnarong N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Background: Primary angle-closure glaucoma (PACG) is more common among Asians than among Caucasians. Acute primary angle closure (APAC) is a serious associated complication in PACG patients. When conventional treatment fails, Anterior Chamber Paracentesis (ACP) can be performed to decrease IOP. Although slit knives are commonly used for performing ACP, other techniques can also be used to perform this procedure. Objective: To investigate the efficacy and safety of immediate anterior chamber paracentesis using a 30-gauge needle combined with conventional topical and systemic medications for the treatment of APAC. Materials and methods: This prospective study was conducted in 15 consecutive primary angle-closure glaucoma patients that presented with and who were treated for acute primary angle closure (APAC) at the Department of Ophthalmology, Siriraj Hospital, (Bangkok, Thailand) during the January 2015 to December 2015 study period. Patients were included if they were older than 18 years of age, if this was their first known attack of APAC, and if they had an IOP ≥ 40 mmHg. Results: Mean age of the 15 included participants (3 males, 12 females) was 61 years. Mean presenting IOP ± SD was 54.3 ± 11.6 mmHg. Twelve of 15 eyes had visual acuity worse than 6/18. Immediately after ACP, mean IOP ± SD was 7.5 ± 5.1 mmHg. None of the 15 included eyes were reactive to light prior to ACP. Mean pupil diameter was significantly reduced from baseline at 60 minutes after ACP (p=0.004) and was significantly smaller than baseline at 24 h after ACP (p=0.03). BCVA was improved to ≥ 6/18 in 11 and 12 eyes at 1 and 24 h after ACP, respectively. All patients had relief from symptoms immediately following ACP. No ACP-related complications were observed in any patient in this study. Conclusion: Immediate APC with a 30-guage needle is a safe and effective initial treatment for APAC. APC should be combined with conventional treatment with topical and/or systemic medications. APC yields rapid IOP reduction, dramatic relief of symptoms, and corneal clarity. APC may also improve response to further treatment, improve IOP control, and may reduce or eliminate the need for systemic medication. Keywords: Anterior chamber paracentesis; 30-gauge needle; Acute of LPI. Systemic anti-glaucoma medication is associated with several primary angle closure; Glaucoma known side effects, as well as some contraindications in specific conditions. Previous studies have reported Anterior Chamber Background Paracentesis (ACP) as a method for managing acute and otherwise unmanageable increases in IOP [8-10]. Lam, et al. reported the The prevalence of Primary Angle-Closure Glaucoma (PACG) has effectiveness of immediate ACP with a sterile 15 degree slit knife been reported to be higher in Asian populations than in Caucasian combined with systemic and topical anti-glaucoma medications [11]. populations [1-3]. Patients with APAC usually present with severe They reported rapid control of IOP, improved corneal clarity, and relief ocular symptoms, such as acute ocular pain, blurry vision, and redness. from APAC-related symptoms. Although slit knives are commonly Prompt treatment is necessary to prevent irreversible damage to ocular used for performing ACP, other techniques can also be used to structures, including anterior chamber angle, endothelial cells, and the perform this procedure. optic nerve. The extent of damage depends on the duration of the acute episode and the level of IOP [4]. The aim of this study was to investigate the efficacy and safety of immediate anterior chamber paracentesis using a 30-gauge needle Conventional management includes combined topical and systemic combined with conventional topical and systemic medications for the medications, and Laser Peripheral Iridotomy (LPI) [5-7]. Given that treatment of APAC. the conventional treatment protocol occasionally fails to reduce IOP, additional interventions are sometimes required. High IOP results in cloudy cornea, which is an important factor that affects the success rate J Clin Exp Ophthalmol, an open access journal Volume 8 • Issue 3 • 1000657 ISSN:2155-9570 Citation: Kitnarong N, Boonyaleepun S, Sakiyalak D, Ruangvaravate N, Metheetrairut A (2017) Immediate Anterior Chamber Paracentesis with a 30-Gauge Needle for Acute Primary Angle Closure. J Clin Exp Ophthalmol 8: 657. doi:10.4172/2155-9570.1000657 Page 2 of 5 Materials and Methods Statistical analysis This prospective study was conducted in 15 consecutive primary Data were analyzed using SPSS Statistics version 11.0 for window angle-closure glaucoma patients that presented with and who were (SPSS, Inc., Chicago, IL, USA). Categorical data are presented as treated for acute primary angle closure (APAC) at the Department of number and continuous data are presented as mean ± standard Ophthalmology, Siriraj Hospital, Bangkok, Thailand during the deviation. Demographic data were summarized using descriptive January 2015 to December 2015 study period. Siriraj Hospital is statistics. Paired t-test was used to compare IOP, corneal edema Thailand’s largest university-based national tertiary referral center. grading and pupil diameter before and after APC treatment. A p-value Written informed consent was obtained from all patients prior to their of less than 0.05 was regarded as being statistically significant. inclusion in this study. The protocol for this study was approved by the Siriraj Institutional Review Board (SIRB), Faculty of Medicine Siriraj Results Hospital, Mahidol University, Bangkok, Thailand (ClinicalTrials.gov.identifier: NCT01923454). This study complied Mean age of the 15 included participants (3 males, 12 females) was with all of the principles set forth in the Declaration of Helsinki (1964) 61 years. All patients were Thai. Demographic and clinical data are and all of its subsequent amendments. shown in Figure 1. Mean presenting IOP ± SD was 54.9 ± 12.2 mmHg. Twelve of 15 eyes had visual acuity worse than 6/18. Immediately after Patients meeting all of the following criteria were included: 1) age ACP, mean IOP ± SD was 7.8 ± 4.5 mmHg. Mean IOP then became >18 years; 2) first known attack of APAC; and, 3) IOP ≥ 21 mmHg. 16.0, 20.5, 26.3, 9.5, and 9.3 mmHg at 15 minutes, 30 minutes, 1 h, 24 Patients meeting any one of the following criteria were excluded: 1) h, and 48 h after the procedure, respectively. The sequential change in patients that declined ACP or that were uncooperative during the ACP IOP is shown in Figure 1. The corresponding mean pupil size is given procedure; 2) patients with APAC in the only remaining eye; 3) in Figure 2. None of the 15 included eyes were pupillary reactive to patients who received any glaucoma treatments prior to the study; 4) light prior to ACP. Mean pupil diameter at presentation was 5.0 ± 0.9 patients with secondary causes of acute angle closure; 5) patients with mm (range: 3.5-7). Mean pupil size was significantly reduced from history of previous intraocular inflammation, ocular infection or baseline at 60 minutes (p=0.004) and at 24 h (p<0.001) after ACP. ocular trauma ; 6) patients with APAC in an eye with history of previous intraocular surgery; and, 7) patients with known hypersensitivity to tetracaine hydrochloride or tobramycin. At presentation, ocular examination included best-corrected visual acuity (BCVA), IOP measured by Goldman applanation tonometry, corneal edema grading, pupil size, and gonioscopy (by Shaffer grading system). Corneal edema grading was, as follows: grade 0=no corneal edema; grade 1=only mild corneal haze noted; grade 2=iris details blurred; grade 3=iris details only scantly visible; grade 4=iris details not visible. Before the ACP procedure, patients received instillation of tetracaine hydrochloride and tobramycin eye drop. A lid speculum was then placed in the involved eye. Anterior chamber paracentesis was performed by NK or SB using sterile technique at the slit-lamp biomicroscope. A sterile 30-gauge needle was connected to a 1 ml insulin syringe. Before the procedure, the plunger was removed from the 1 ml insulin syringe to allow for the free flow of aqueous humor. The 30-gauge needle was then passed through the temporal side of the mid-peripheral cornea to create a self-sealing side port. A sterile cotton swab was positioned at the nasal side of the limbus to stabilize the Figures 1: Mean intraocular pressure (IOP) at various time points globe and to counter the force of the needle during the procedure. The before and after paracentesis with a 30-gauge needle in 15 patients 30-gauge needle tip was maintained within the anterior chamber until with acute primary angle closure. aqueous appeared in the needle hub or until there was no further aqueous flow.
Load more

Recommended publications
  • Pharmacy Phacts in This Issue Pharmd Candidates Discuss Oral Health and Preventing Eye Strain at Work
    Pharmacy Phacts In this issue PharmD candidates discuss Oral Health and Preventing Eye Strain At Work Oral Health Landon Forrest Stewart, PharmD Candidate 2021 Why is Oral Health important? Oral health is an important part of our overall health. Oral health issues can cause oral pain, increased costs in healthcare, and less productivity. Recent developments in oral hygiene have led to improved outcomes for patients. Many oral health issues are still prevalent today, but the good news is that many are preventable with daily healthy habits. Healthy habits are required to maintain good oral health and many oral health issues are still prevalent today. One of the most common oral health problems is decay in the tooth also known as a cavity. The outer layer of the tooth is a tough mineral layer called the enamel. Bacteria group together on teeth to form plaques that can erode the enamel and the deeper layers of your teeth, causing cavities. Cavities are present and untreated in up to 26% up American adults. (1) If left untreated, they can lead to pain in the tooth and more severe infections known as an abscess. Another common oral health problem is gum disease. When bacteria group together on the teeth, it causes the immune system to respond and causes inflammation in the mouth. The initial inflammation is called gingivitis and makes your gums swell and bleed more easily. Untreated gingivitis can progress to a more severe gum disease called periodontitis. Periodontitis can damage the structure that holds your teeth in place and is a common cause of tooth loss.
    [Show full text]
  • Study Protocol
    RESEARCH PROTOCOL Project Title A multicenter, single blind, randomized controlled trial of virucidal effect of Polyvinylpyrrolidone-Iodine on SARS-CoV-2 as well as safety of its application on nasopharynx & oropharynx of COVID-19 positive patients BMRC Reg. No: 38624012021 Page-1/17 Project Title A multicenter, single blind, randomized controlled trial of virucidal effect of Polyvinylpyrrolidone- Iodine on SARS-CoV-2 as well as safety of its application on nasopharynx & oropharynx of COVID- 19 positive patients. Summary Povidone Iodine (Iodine with water soluble polymer Polyvinylpyrolidone) or PVP-I is a proven and time trusted antiseptic agent having best possible (99.99%) virucidal effect in it‟s only 0.23% concentration, against all viruses including SARS-Co, MERS-CoV; even in SARS-COV-2 due to it‟s nonspecific mode of action for virus killing and having no resistance [1,2]. Corona virus is transmitted by/via respiratory droplets or aerosol, produced from sneezing or coughing of infected persons to healthy individual through mouth and nose mainly [5, 6]. The routes of entry of coronavirus in human body are mouth, nose and eye. PVP-I products for gargling the throat and spraying or washing the nose may have a preventive effect on COVID-19 and if it is proved in this study following human trial, this will be a landmark research in COVID-19 pandemic. In line of this, PVP-I containing oro-nasal spray, proposed Bangasafe, which should be regarded as PONS (Povidone Iodine oro-nasal spray) in this protocol, has been developed and proposed to use against corona virus disease.
    [Show full text]
  • Viscotears Liquid Gel Later Than Four Weeks After First Opening
    Viscotears® Liquid Gel carbomer (polyacrylic acid) Patient Information Leaflet This product will be called Viscotears in this leaflet. Please read this leaflet carefully before you start to use Viscotears. It contains important information. Keep the leaflet in a safe place because you may want to read it again. Do not share these eye drops with anyone else just in case you have an eye infection which you could pass on. If you have any other questions, or if there is something you don’t understand, please ask your pharmacist. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. In this leaflet: 1. What Viscotears is and what it’s used for 2. Things to consider before you start to use Viscotears 3. How to use Viscotears 4. Possible side effects 5. How to store Viscotears 6. Further information 1. What Viscotears is and what it’s used for Viscotears contains the active ingredient, carbomer (polyacrylic acid). Viscotears is used to make your eyes more comfortable when they feel dry. It is one of a group of eye drops called ‘artificial tears’. 2. Things to consider before you start to use Viscotears DO NOT use Viscotears if: If you are allergic to carbomer or any of the other ingredients of this medicine (listed in section 6). Take special care: In children and adolescents aged to 18 years, the safety and efficacy of Viscotears at the posology recommended in adults has been established by clinical experience, but no clinical trial data are available.
    [Show full text]
  • Formulary Drug List
    AMLODIPINE ORAL SUSPENSION Products Affected Step 2: • KATERZIA 1 MG/ML ORAL SUSPENSION Details Criteria PRIOR CLAIM FOR GENERIC AMLODIPINE TABLETS WITHIN THE PAST 120 DAYS. 1 ANTIBACTERIALS (EENT) Products Affected Step 2: • BESIVANCE 0.6 % EYE DROPS,SUSPENSION Details Criteria PRIOR CLAIM FOR FORMULARY VERSION OF CIPROFLOXACIN OPHTHALMIC OR OFLOXACIN OPHTHALMIC DROPS WITHIN THE LAST 120 DAYS. 2 ANTIDEPRESSANTS Products Affected Step 2: • FETZIMA 120 MG CAPSULE,EXTENDED RELEASE CAPSULE,EXTENDED RELEASE • FETZIMA 40 MG • FETZIMA 20 MG (2)-40 MG (26) CAPSULE,EXTENDED RELEASE CAPSULE,EXTENDED RELEASE,24 • FETZIMA 80 MG HR,DOSE PACK CAPSULE,EXTENDED RELEASE • FETZIMA 20 MG Details Criteria PRIOR CLAIM FOR TRINTELLIX AND VIIBRYD WITHIN THE PAST 365 DAYS. 3 ANTIPSYCHOTIC AGENTS Products Affected Step 2: • aripiprazole 10 mg disintegrating tablet • FANAPT 4 MG TABLET • aripiprazole 15 mg disintegrating tablet • FANAPT 6 MG TABLET • asenapine 10 mg sublingual tablet • FANAPT 8 MG TABLET • asenapine 2.5 mg sublingual tablet • SECUADO 3.8 MG/24 HOUR • asenapine 5 mg sublingual tablet TRANSDERMAL 24 HOUR PATCH • CAPLYTA 42 MG CAPSULE • SECUADO 5.7 MG/24 HOUR • clozapine 100 mg disintegrating tablet TRANSDERMAL 24 HOUR PATCH • clozapine 12.5 mg disintegrating tablet • SECUADO 7.6 MG/24 HOUR • clozapine 150 mg disintegrating tablet TRANSDERMAL 24 HOUR PATCH • clozapine 200 mg disintegrating tablet • VERSACLOZ 50 MG/ML ORAL • clozapine 25 mg disintegrating tablet SUSPENSION • FANAPT 1 MG TABLET • VRAYLAR 1.5 MG (1)-3 MG (6) • FANAPT 10 MG TABLET CAPSULES
    [Show full text]
  • Handbook ESRA
    TECHNIQUES HEAD & NECK 4 Intracranial surgery p. 3 Eye blocks p. 5 Face anatomy p. 16 Face particularity p. 23 Ophtalmic nerve blocks p. 27 Maxillary nerve blocks p. 33 Mandibular nerve blocks p. 46 THORAX & ABDOMEN 50 Epidural anaesthesia in Cardio-thoracic surgery p. 50 Ilioinguinal-Iliohypogastric block p. 55 Peri-umbilical & Rectus sheath block p. 57 Pudendal block p. 58 UPPER LIMB 61 Choice of a technique p. 61 Brachial plexus anatomy p. 65 Interscalen block p. 68 Supraclavicular blocks p. 73 Infraclavicular blocks p. 80 Axillary block p. 83 LOWER LIMB 90 Lumbar plexus block p. 90 Iliofascial block p. 100 Obturator block p. 102 Sciatic blocks o Sciatic blocks - parasacral nerve approach p. 109 o Sciatic blocks - posterior popliteal approach p. 115 Ankle blocks p. 119 AXIAL BLOCKS 123 Lumbar epidural p. 123 OBSTETRICS AXIAL BLOCKS 126 Epidural p. 126 PERIPHERAL BLOCKS Pudendal block p. 58 2 Aknowledgement The provenience of the materials included in this handbook is from the Learning Zone on the official site of “European Society of Regional Anesthesia and Pain Therapy”. http://www.esra-learning.com/ 2007 3 HEAD & TABLE OF CONTENTS NECK • Intracranial surgery • Eye blocks • Face anatomy • Face particularity • Ophtalmic nerve blocks • Maxillary nerve blocks • Mandibular nerve blocks • Cervical plexus blocks HEAD & INTRACRANIAL SURGERY NECK Paul J. Zetlaoui, M.D. Kremlin-Bicetre - France In intra-cranial neurosurgery, scalp infiltration aims to prevent systematic and cerebral hemodynamic variations, contemporary of skin incision. The potential morbidity of these hypertension-tachycardia episodes, even in patients profoundly anaesthetized, is secondary in the increase of the cerebral blood flow and in its deleterious consequences on intra-cranial pressure in these compromised patients.
    [Show full text]
  • A Potential Alternative Orodispersible Formulation to Prednisolone Sodium Phosphate Orally Disintegrating Tablets
    pharmaceutics Article A Potential Alternative Orodispersible Formulation to Prednisolone Sodium Phosphate Orally Disintegrating Tablets Essam A. Tawfik 1,2,* , Mariagiovanna Scarpa 2, Hend E. Abdelhakim 2 , Haitham A. Bukhary 2,3, Duncan Q. M. Craig 2 , Susan A. Barker 4 and Mine Orlu 2 1 National Center for Pharmaceutical Technology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology, P.O. Box 6086, Riyadh 11442, Saudi Arabia 2 Department of Pharmaceutics, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK; [email protected] (M.S.); [email protected] (H.E.A.); [email protected] (H.A.B.); [email protected] (D.Q.M.C.); [email protected] (M.O.) 3 Department of Pharmaceutics, College of Pharmacy, Umm Al-Qura University, Makkah 24381, Saudi Arabia 4 Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building Central Avenue, Chatham, Kent ME4 4TB, UK; [email protected] * Correspondence: etawfi[email protected] Abstract: The orally disintegrating tablet (ODT) has shown vast potential as an alternative oral dosage form to conventional tablets wherein they can disintegrate rapidly (≤30 s) upon contact with saliva fluid and should have an acceptable mouthfeel as long as their weight doesn’t exceed 500 mg. However, owing to the bitterness of several active ingredients, there is a need to find a suitable alternative to ODTs that maintains their features and can be taste-masked more simply and inexpensively. Therefore, electrospun nanofibers and solvent-cast oral dispersible films (ODFs) are used in this study as potential OD formulations for prednisolone sodium phosphate (PSP) that is Citation: Tawfik, E.A.; Scarpa, M.; commercially available as ODTs.
    [Show full text]
  • Can Pilocarpine Eye Drops Be Used to Treat Dry Mouth?
    Page 1 of 5 Question: Can pilocarpine eye drops be used to treat dry mouth? July 2019 Summary Pilocarpine is not recommended as a first line treatment for dry mouth (xerostomia). However, saliva stimulants are generally more effective than saliva substitutes (unless a main salivary duct is blocked) 1, and are preferred by patients.2 Other saliva stimulants such as sugar-free chewing gum should be tried prior to the initiation of pilocarpine. Pilocarpine tablets (Salagen®) are unlicensed in Ireland but are licensed in the UK for the treatment of dry mouth following irradiation for head and neck cancer and for patients with Sjögren's syndrome.3 There is limited information available to support the oral use of pilocarpine eye drops as an alternative. The use of pilocarpine eye drops to treat a dry mouth is unlicensed. For cost/reimbursement reasons, pilocarpine eye drops administered orally are favored over the use of Salagen® oral tablets (unlicensed). A recommended dose of 5mg - 10mg three times daily of oral pilocarpine tablets is approximately equivalent to pilocarpine 4% w/v, 3 - 5 drops (6mg-10mg) taken orally three times daily. 1 - 6 Palliative Meds Info: Terms and Conditions The information outlined above is intended for healthcare professionals only. The information outlined above is believed to accurately reflect the medical literature at the time of writing. Healthcare professionals must use their own judgment to determine the accuracy and relevance of the information. See www.olh.ie for full terms and conditions. Page 2 of 5 Availability Pilocarpine tablets are indicated for the treatment of dry mouth following irradiation for head and neck cancer and for dry mouth and dry eyes in Sjogren’s syndrome.
    [Show full text]
  • Procedure Pricing
    Procedure Pricing The information provided below by Lake Health is a comprehensive list of charges for each inpatient and outpatient service or item provided by our hospital, also known as a chargemaster. It is not a helpful tool for patients to comparison shop between hospitals or to estimate what health care services are going to cost them out of their own pocket. For more information about the cost of your care, please contact our Financial Counselor staff at 440-602-6682. *These prices are correct as of July 1, 2020. LH Default Tech Name Price 14.3.3 ETA PROTEIN, SERUM $ 336.00 5 HIAA URINE RANDOM $ 169.00 5-HIAA URINE 24HR $ 169.00 6 T G METABOLITE $ 378.00 6MMP METABOLITE $ 397.00 7C4 BILE ACID BY LC MS/MS $ 468.00 96372 IM SUG IM SUB Q ADMIN $ 205.00 A LINE INSERTION $ 1,050.00 ABD PARACENTESIS W/O IMAGING $ 1,445.00 ABD PARACENTESIS WITH IMAGING $ 1,775.00 ABDOMINAL BINDER LARGE $ 107.00 ABDOMINAL BINDER X-LARGE $ 20.00 ABLATE ARRHYTHMIA ADD ON $ 10,525.00 ABLATION AV NODE CHB $ 19,955.00 ABRASION SINGLE LESION $ 248.00 ACAPELLA_FLUTTER $ 111.00 ACCUPAP $ 79.00 ACETAMINOPHEN $ 222.00 ACETYLCHOLINE RECEPTOR BINDING AB $ 413.00 ACETYLCHOLINE RECP BLOCKING AB $ 393.00 ACETYLOCHOLINE RECP MOD AB $ 393.00 ACID AGAR $ 49.00 ACID FAST SMEAR $ 90.00 ACNE SURGERY $ 164.00 ACREMONIUM KILIENSE IGE ALLERGEN $ 16.00 ACT EACH $ 87.00 ACTH $ 244.00 ACTH STIMULATION PANEL $ 225.00 ACTIN,IHC $ 365.00 ACTIVATED PROTEIN C $ 101.00 ACTV WOUND MGMT W/DEBRIDEMENT FIRST 20 SQ CM $ 179.00 ACUTE HEPATITIS PANEL $ 244.00 ADDL IV MED PUSH SAME DRUG $ 277.00
    [Show full text]
  • Consent to Medical -Surgical Procedure and Administration of Anesthesia
    Consent to Medical -Surgical Procedure and Administration of Anesthesia Procedure Scheduled at: Springview Hospital Health South Other: _ Surgeon: Thomas G. Abell, MD unless noted otherwise here: Physician's Surgical Procedure Disclosure and Patients Consent TO THE PATIENT: You have the right to be informed about your condition and the recommended surgical, medical or diagnostic procedure so that you may make the decision whether or not to undergo the procedures after knowing the risks involved and any treatment alternatives available to you. This information is not meant to alarm you; it is an effort to make you better informed so that you may give or withhold your consent to the procedure. If you do not understand any of the information provided, ask your physician to explain it. 1. DIAGNOSIS: I (we) voluntarily request my physician, Thomas G. Abell, MD., and such associates, technical assistants, and other health care providers as they may deem necessary, to treat my CONDITION and perform procedure(s) PHACOEMULSIFICATION CATARACT EXTRACTION WITH INTRA-OCULAR LENS IMPLANTATION. This procedure, including, preoperative preparation, lab work (if needed), eye drop use/instillation, postoperative care, has been explained and reviewed with me. 2. PROCEDURE(S): I (we) understand that the following surgical procedure or procedures are planned for me on or about RIGHT EYE LEFT EYE . I voluntarily consent to and authorize this (these) PROCEDURE(S) because it : (PLEASE HAVE PT INITIAL NEXT TO THEIR SELECTION) __ Interferes with my ability to maintain
    [Show full text]
  • Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents
    pharmaceutics Review Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents Eliana B. Souto 1,2,*, João Dias-Ferreira 1 , Ana López-Machado 3,4, Miren Ettcheto 5,6, Amanda Cano 3,4,5, Antonio Camins Espuny 5,6 , Marta Espina 3,4 , Maria Luisa Garcia 3,4,5 and Elena Sánchez-López 1,3,4,5,* 1 Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, 3000-458 Coimbra, Portugal 2 CEB—Centre of Biological Engineering, University of Minho, Campus de Gualtar 4710-057 Braga, Portugal 3 Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain 4 Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08028 Barcelona, Spain 5 Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), University of Barcelona, 08028 Barcelona, Spain 6 Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain * Correspondence: ebsouto@ff.uc.pt (E.B.S.); [email protected] (E.S.-L.); Tel.: +351-239-488-400 (E.B.S.); +34-696-793-679 (E.S.-L.) Received: 6 August 2019; Accepted: 26 August 2019; Published: 6 September 2019 Abstract: The eye presents extensive perspectives and challenges for drug delivery, mainly because of the extraordinary capacity, intrinsic to this path, for drugs to permeate into the main circulatory system and also for the restrictions of the ocular barriers. Depending on the target segment of the eye, anterior or posterior, the specifications are different. The ocular route experienced in the last decades a lot of progresses related with the development of new drugs, improved formulations, specific-designed delivery and even new routes to administer a drug.
    [Show full text]
  • Faith Regional Health Services List of Charges Note: Any Items with an '*' Do Not Have a Fixed Charge. the Charge Is Manually A
    Faith Regional Health Services List of Charges Note: Any items with an '*' do not have a fixed charge. The charge is manually adjusted for patient-specific items. Charge# Pricing Transparency Description 2019 Price 17517 NEWBORN NURSERY $ 821.00 22004 INTENSIVE CARE ROOM 3,456.00 25304 PEDIATRICS INTERMEDIATE (LEVEL 2) 1,931.00 27516 NEWBORN INTERMEDIATE 1,931.00 32011 INTENSIVE CARE STEP DOWN ROOM 2,279.00 34819 MEDICAL SURGICAL ROOM 1,500.00 35311 WOMEN'S SURGERY 1,500.00 36509 BEHAVORIAL HEALTH ROOM 2,224.00 37515 NEWBORN INTENSIVE CARE (NICU) 2,673.00 38000 ACUTE REHAB INTERRUPTED STAY * 42010 MEDICAL SURGICAL ROOM 1,500.00 45310 PEDIATRICS LEVEL 1 1,500.00 46425 PROGRESSIVE PSYCH ROOM 2,224.00 46524 BEHAVORIAL HEALTH ROOM 2,224.00 48009 ACUTE REHAB PRIVATE ROOM 1,662.00 55004 POST-PARTUM 1,532.00 56424 PROGRESSIVE PSYCH ROOM 2,224.00 56523 BEHAVORIAL HEALTH ROOM 2,224.00 99002 RM AMS SAME DAY SURG BED * 101394 CAR SEAT TESTING 60MIN. 101.00 101410 CAR SEAT TESTING +30 101.00 105510 OBSERVATION INTENSIVE CARE DIRECT ADMIT 621.00 105528 OBSERVATION INTENSIVE CARE FIRST 6 HOURS 1,252.00 105536 OBSERVATION INTENSIVE CARE HOURS 7 THROUGH 12 124.00 105544 OBSERVATION INTENSIVE CARE HOURS 13 THROUGH 18 62.00 105551 OBSERVATION INTENSIVE CARE HOURS 19 THROUGH 24 62.00 OBSERVATION INTENSIVE CARE OVER 24 HOURS (PER HOUR 105569 62.00 CHARGE) 105577 OBSERVATION MEDICAL SURGICAL DIRECT ADMIT 621.00 105585 OBSERVATION MEDICAL SURGICAL FIRST 6 HOURS 1,252.00 105593 OBSERVATION MEDICAL SURGICAL HOURS 7 THROUGH 12 124.00 105601 OBSERVATION MEDICAL SURGICAL HOURS 13 THROUGH 18 62.00 105619 OBSERVATION MEDICAL SURGICAL HOURS 19 THROUGH 24 62.00 OBSERVATION MEDICAL SURGICAL OVER 24 HOURS (PER HOUR 105627 62.00 CHARGE) 105635 OB OBSERVATION DIRECT ADMIN.
    [Show full text]
  • Instilling Eye Drops
    Instilling Eye Drops This material will help you understand eye drops and how to properly use them. What are the different types of eye drops? There are two different kinds of eye drops for patient use: over-the- counter and prescription. You can buy over-the-counter eye drops without a prescription from your doctor, but you still need to use them as directed. Artificial tears are one kind of over-the-counter eye drops, and are used to soothe dry or irritated eyes. Your doctor may also prescribe steroid eye drops, eye drops to treat infections, or those that treat glaucoma. When using eye drops, you should always follow your doctor’s directions and those written on the package. How do I insert eye drops? Many people find it easiest to put in their eye drops in front of a mirror. To insert eye drops into your eyes, follow these steps: 1. Before using your eye drops, wash your hands. 2. Remove the cap. Do not touch the tip of the bottle. 3. Slightly tilt your head back. Kellogg Eye Center – Glaucoma Clinic Instilling Eye Drops 1 4. Pull your lower eyelid down with your index finger to make a “pocket” with your lower lid, as seen in Picture 1. 5. Hold the tip of the bottle directly over this “pocket”. 6. While looking up, let the eye drop fall into the “pocket”. (Do not touch the bottle to your eye or Picture 1 eyelid.) 7. Close your eyes. 8. Using your finger, apply pressure where the lids meet the nose with your eyes closed, as seen in Picture 2.
    [Show full text]